S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:REPH

Recro Pharma (REPH) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$1.47
▼
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

REPH stock logo

About Recro Pharma (NASDAQ:REPH) Stock

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

REPH Stock News Headlines

June 24, 2022 | benzinga.com
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL
April 20, 2022 | reuters.com
Societal CDMO Inc
May 29, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
March 22, 2022 | finanznachrichten.de
Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
March 22, 2022 | finance.yahoo.com
Is Recro Pharma (REPH) a Worthy Investment?
March 1, 2022 | benzinga.com
Recap: Recro Pharma Q4 Earnings
February 23, 2022 | finance.yahoo.com
Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility
February 22, 2022 | finance.yahoo.com
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
May 29, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
January 26, 2022 | finance.yahoo.com
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
January 3, 2022 | finance.yahoo.com
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
December 8, 2021 | finance.yahoo.com
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
November 2, 2021 | finance.yahoo.com
Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021
October 27, 2021 | finance.yahoo.com
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
September 21, 2021 | marketwatch.com
Recro Pharma Signs Renewable Energy Agreement with Georgia Power
September 21, 2021 | finance.yahoo.com
Recro Signs Renewable Energy Agreement With Georgia Power
September 16, 2021 | finance.yahoo.com
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
August 16, 2021 | bizjournals.com
Recro Pharma goes bicoastal with 'transformative' acquisition of San Diego firm for $50M
August 13, 2021 | marketwatch.com
Recro Pharma Buys San Diego-Based Irisys for $50 Million >REPH
August 13, 2021 | finance.yahoo.com
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
August 10, 2021 | finance.yahoo.com
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
August 7, 2021 | markets.businessinsider.com
Recro Pharma is about to announce its earnings — here's what to expect
August 6, 2021 | markets.businessinsider.com
Recro Pharma Inc hosts conference call for investors
August 2, 2021 | finance.yahoo.com
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
July 20, 2021 | finance.yahoo.com
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
July 13, 2021 | finance.yahoo.com
Recro Enters Development and Manufacturing Agreement With New Client
May 13, 2021 | bizjournals.com
Recro plans $30M stock sale; spinoff seeks to increase its amount of authorized shares
See More Headlines

Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

REPH Company Calendar

Last Earnings
3/01/2022
Today
5/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPH
CUSIP
N/A
CIK
1588972
Web
www.recropharma.com
Phone
(770) 534-8239
Fax
484-395-2471
Employees
185
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-11,370,000.00
Net Margins
-15.15%
Pretax Margin
-15.09%
Return on Equity
-56.66%
Return on Assets
-11.14%

Debt

Debt-to-Equity Ratio
2.27
Current Ratio
3.24
Quick Ratio
2.74

Sales & Book Value

Annual Sales
$75.36 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
56,424,000
Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08

Key Executives

  • J. David EnloeJ. David Enloe
    President, Chief Executive Officer & Director
  • Ryan D. Lake
    Chief Financial Officer & Treasurer
  • Richard Sidwell
    Chief Scientific Officer & Senior Vice President
  • Stephen Dress
    Director-Information Technology
  • David Smithwick
    Vice President-Technical Operations

Key Competitors

View All Competitors













REPH Stock - Frequently Asked Questions

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) issued its quarterly earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return on equity of 56.66%. During the same period in the prior year, the company posted ($0.48) EPS.

What other stocks do shareholders of Recro Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Recro Pharma investors own include TherapeuticsMD (TXMD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP) and Ocular Therapeutix (OCUL).

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How much money does Recro Pharma make?

Recro Pharma (NASDAQ:REPH) has a market capitalization of $0.00 and generates $75.36 million in revenue each year. The specialty pharmaceutical company earns $-11,370,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

How many employees does Recro Pharma have?

The company employs 185 workers across the globe.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The official website for the company is www.recropharma.com. The specialty pharmaceutical company can be reached via phone at (770) 534-8239, via email at sam@argotpartners.com, or via fax at 484-395-2471.

This page (NASDAQ:REPH) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -